

RED CELLS, IRON, AND ERYTHROPOIESIS

Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study

Rachael F. Grace,¹ Paola Bianchi,² Eduard J. van Beers,³ Stefan W. Eber,⁴ Bertil Glader,⁵ Hassan M. Yaish,⁶ Jenny M. Despotovic,⁷ Jennifer A. Rothman,⁸ Mukta Sharma,⁹ Melissa M. McNaull,¹⁰ Elisa Fermo,² Kimberly Lezon-Geyda,¹¹ D. Holmes Morton,^{12,13} Ellis J. Neufeld,¹⁴ Satheesh Chonat,¹⁵ Nina Kollmar,¹⁶ Christine M. Knoll,¹⁷ Kevin Kuo,¹⁸ Janet L. Kwiatkowski,¹⁹ Dagmar Pospíšilová,²⁰ Yves D. Pastore,²¹ Alexis A. Thompson,²² Peter E. Newburger,²³ Yaddanapudi Ravindranath,²⁴ Winfred C. Wang,¹⁴ Marcin W. Wlodarski,²⁵ Heng Wang,²⁶ Susanne Holzhauser,²⁷ Vicky R. Breakey,²⁸ Joachim Kunz,²⁹ Sujit Sheth,³⁰ Melissa J. Rose,³¹ Heather A. Bradeen,³² Nolan Neu,¹ Dongjing Guo,¹ Hasan Al-Sayegh,¹ Wendy B. London,¹ Patrick G. Gallagher,¹¹ Alberto Zanella,² and Wilma Barcellini²

¹Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, MA; ²Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy; ³Universitair Medisch Centrum Utrecht, Utrecht, The Netherlands; ⁴Schwerpunktpraxis für Pädiatrische Hämatologie-Onkologie, Munich, Germany; ⁵Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; ⁶Primary Children's Hospital, University of Utah, Salt Lake City, UT; ⁷Texas Children's Hematology Center, Baylor College of Medicine, Houston, TX; ⁸Duke University Medical Center, Durham, NC; ⁹Children's Mercy Hospital, Kansas City, MO; ¹⁰University of Mississippi Medical Center, Jackson, MS; ¹¹Yale University School of Medicine, New Haven, CT; ¹²Central Pennsylvania Clinic for Special Children and Adults, Belleville, PA; ¹³Lancaster General Hospital, Lancaster, PA; ¹⁴St. Jude Children's Research Hospital, Memphis, TN; ¹⁵Emory University School of Medicine, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA; ¹⁶Klinikum Kassel GmbH, Kassel, Germany; ¹⁷Phoenix Children's Hospital, Phoenix, AZ; ¹⁸University of Toronto, University Health Network, Toronto, ON, Canada; ¹⁹Children's Hospital of Pennsylvania and Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA; ²⁰Fakultni Nemocnice Olomouc, Olomouc, Czech Republic; ²¹Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada; ²²Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; ²³University of Massachusetts Memorial Children's Medical Center, Worcester, MA; ²⁴Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, MI; ²⁵Division of Pediatric Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; ²⁶DDC Clinic for Special Needs Children, Middlefield, OH; ²⁷Charite, Berlin, Germany; ²⁸McMaster University, Hamilton, ON, Canada; ²⁹Zentrum für Kinder-und Jugendmedizin, Heidelberg, Germany; ³⁰Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY; ³¹Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH; and ³²The University of Vermont Children's Hospital, Burlington, VT

KEY POINTS

- PK deficiency manifests a broad spectrum in anemia severity that moderately improves after splenectomy.
- Close attention to monitoring for iron overload, gallstones, and other complications is recommended in all patients with PK deficiency.

An international, multicenter registry was established to collect retrospective and prospective clinical data on patients with pyruvate kinase (PK) deficiency, the most common glycolytic defect causing congenital nonspherocytic hemolytic anemia. Medical history and laboratory and radiologic data were retrospectively collected at enrollment for 254 patients with molecularly confirmed PK deficiency. Perinatal complications were common, including anemia that required transfusions, hyperbilirubinemia, hydrops, and prematurity. Nearly all newborns were treated with phototherapy (93%), and many were treated with exchange transfusions (46%). Children age 5 years and younger were often transfused until splenectomy. Splenectomy (150 [59%] of 254 patients) was associated with a median increase in hemoglobin of 1.6 g/dL and a decreased transfusion burden in 90% of patients. Predictors of a response to splenectomy included higher presplenectomy hemoglobin ($P = .007$), lower indirect bilirubin ($P = .005$), and missense *PKLR* mutations ($P = .0017$). Postsplenectomy thrombosis was reported in 11% of patients. The most frequent complications included iron overload (48%) and gallstones (45%), but other complications such as aplastic crises, osteopenia/bone fragility, extramedullary

hematopoiesis, postsplenectomy sepsis, pulmonary hypertension, and leg ulcers were not uncommon. Overall, 87 (34%) of 254 patients had both a splenectomy and cholecystectomy. In those who had a splenectomy without simultaneous cholecystectomy, 48% later required a cholecystectomy. Although the risk of complications increases with severity of anemia and a genotype-phenotype relationship was observed, complications were common in all patients with PK deficiency. Diagnostic testing for PK deficiency should be considered in patients with apparent congenital hemolytic anemia and close monitoring for iron overload, gallstones, and other complications is needed regardless of baseline hemoglobin. This trial was registered at www.clinicaltrials.gov as #NCT02053480. (*Blood*. 2018;131(20):2183-2192)

Introduction

Red cell pyruvate kinase (PK) deficiency is a rare congenital, nonspherocytic hemolytic anemia caused by a glycolytic defect that is due to compound heterozygous or homozygous mutations in the *PKLR* gene on chromosome 1q21.¹ PK catalyzes the conversion of

phosphoenolpyruvate to pyruvate, creating red cell adenosine triphosphate. PK deficiency leads to a reduction in ATP and shortened reticulocyte and red cell lifespan because of an inability to maintain the red cell electrochemical gradient and membrane integrity as well as red cell damage and clearance in the spleen.^{2,3}

The exact prevalence of PK deficiency is not known, although earlier reports have estimated that the prevalence of heterozygous carriers ranges from 1% to 3%, and the prevalence of the disease is 1 per 20 000 in the white population.^{4,5} There is a high frequency of PK deficiency among the Pennsylvania Amish community as a result of a founder effect.⁶ Because of the rarity of PK deficiency, its clinical features have been reported in previous case series mainly at single centers.⁷⁻¹⁰ Clinical features vary widely, ranging from a mildly symptomatic anemia to one that necessitates regular transfusions. The frequency of complications such as jaundice, gallstones, iron overload, severe anemia, thrombosis, and osteopenia is not well understood and has not been studied in a large population of patients with PK deficiency.¹¹

Currently, there are no guidelines for the diagnosis, management, and monitoring of children and adults with PK deficiency. Best practice with regard to transfusion regimen and splenectomy is not known. Management strategies often emulate those of patients with hereditary spherocytosis or thalassemia intermedia, because it is not clear how patients with PK deficiency differ in terms of their risk of complications or clinical course.

The Pyruvate Kinase Deficiency Natural History Study was developed in 2013 with a retrospective and prospective longitudinal cohort to characterize the clinical manifestations, complications, and treatments of patients to support and guide the development of future treatments for PK deficiency.

Methods

Patients

Eligible patients had biochemically or molecularly diagnosed PK deficiency. If patients had prior genetic testing that confirmed 2 pathogenic *PKLR* mutations, the testing was not repeated. If prior genetic testing was not conducted or the results were not available, samples were sent to Ca' Granda Ospedale Maggiore Policlinico Milan or Yale-New Haven Children's Hospital for molecular analysis by Sanger sequencing. To evaluate genotype-phenotype associations, patients ($n = 193$) were grouped according to genotype (2 missense [M/M], 1 missense/1 nonmissense [M/NM], or 2 nonmissense mutations [NM/NM]); NM included nonsense, frameshift, inframe small indel, large deletions, and splicing mutations. Patients with 3 pathogenic variants ($n = 2$) or promoter mutations with unknown pathogenic effects ($n = 4$) were excluded from the genotype-phenotype analysis. Patients from the Amish community (homozygous for the splicing mutation R479H [$n = 55$]) were also excluded from the genotype-phenotype analysis.

The study protocol was approved by each site's institutional review board and/or ethics committee, and all patients gave informed consent. Patients were able to participate from a distance by using signed medical releases or were primarily observed at a center approved to conduct the study. At the time of enrollment, patients' medical records were reviewed retrospectively. Data collected included medical history, examination findings, and laboratory and radiologic studies. Medical history missing from the medical records was obtained by patient recall if known. All transfusion data were collected from medical records. At all sites, except in Lancaster, Pennsylvania, data were collected only if they were obtained for clinical purposes. In

Lancaster, in which all enrolled patients were Amish, additional laboratory and radiologic data were collected under a site-specific institutional review board–approved protocol.

Statistical analysis

Patient demographics, transfusion status, comorbid diagnoses, and other disease characteristics were described with frequencies, proportions, medians, means, ranges, and interquartile ranges as appropriate for sample size. Tests of association were performed using Fisher's exact test, the Wilcoxon rank sum test, or Kruskal-Wallis test. Univariate ordinal logistic regression modeling was performed to identify factors predictive of clinical severity classification. The normalized PK activity was calculated as $[(PK_{obs} - PK_{LL}) \times 100] / (PK_{UL} - PK_{LL})$ where PK_{obs} is the observed PK enzyme value, and PK_{LL} and PK_{UL} are the lower limit and upper limit of the reference range, respectively. Regular transfusions were defined as having ≥ 6 transfusions over a 12-month period. When actual dates were unknown, an approximate date was reported. The description of the transfusion schedules was stratified by age, in which patients younger than age 5 years at enrollment were considered separately from patients age 5 years and older at enrollment. Sample sizes are presented for those with known data available for each variable. P values were two-sided, and P values $< .05$ were considered statistically significant. For the tests in the genotype-phenotype analysis, adjustment for multiple comparisons was performed by applying a significance level of $P < .0055$ instead of $.05$.

Results

Demographics

This study enrolled 278 patients with PK deficiency from June 2014 through April 2017 at 31 centers in 5 countries. After exclusion of ineligible patients because 2 pathogenic *PKLR* mutations could not be confirmed, there were 254 eligible participants. Baseline demographic information is presented in Table 1. Patients from the Amish community ($n = 55$) composed 22% of the total population. Thirty-five percent of patients were related to other participants in the study.

The median normalized PK enzyme activity level was -69% (range, -486% to 118% [$n = 107$]), with 92 patients (86%) categorized as low, 14 (13%) as normal, and 1 (1%) as having high PK enzyme activity.

Perinatal complications

Before birth, when patients with PK deficiency were in utero, perinatal complications were reported in 28% (65 of 233; supplemental Table 1, available on the *Blood* Web site). For these 65 patients, preterm birth (56%), prenatal anemia requiring in utero transfusions (47%), and preterm labor (42%) were reported most commonly. Intrauterine growth retardation and/or fetal distress was reported in 24% of pregnancies, and 16% were complicated by hydrops. One newborn developed severe hepatic disease with evolution to liver failure. The majority (207 [90%] of 230) of newborns with PK deficiency developed an indirect hyperbilirubinemia. Jaundice was treated with phototherapy (93%) and/or exchange transfusion (46%).

Clinical complications

Comorbid diagnoses and complications are listed in Table 1. A history of aplastic crisis was reported in a small subset of

Table 1. Demographic features and common complications of enrolled patients

Characteristics	All (N = 254*)		Amish (n = 55)		Non-Amish (n = 199)	
	n		n		n	
Sex						
Male	124	49%	14	25%	110	55%
Female	130	51%	41	75%	89	45%
Age at diagnosis, y (range)	243†	0.4 (0-60.3)	52	0 (0-10)	191	1.1 (0-60.3)
Age at enrollment, y (range)						
Overall	254	19.0 (0.1-69.9)	55	23.4 (0.2-60)	199	17.6 (0.1-69.9)
<18	123	6.4 (0.1-17.7)	22	7.4 (0.2-16.4)	101	6.1 (0.1-17.7)
≥18	131	36.2 (18.0-69.9)	33	39.8 (18-60.4)	98	35.4 (18.2-69.9)
White race	235	92.5%	55	100%	180	90%
Hispanic ethnicity	18	7.1%	0	0%	18	9%
Median number of lifetime transfusions (range)	191	18 (1-516)	39	12 (1-153)	152	25 (1-516)
Splenectomized	150	59%	51	93%	99	50%
Gallstones	112/248	45%	24	10%	88	35%
Extramedullary hematopoiesis	23/254	9%	15	27%	8	4%
Hepatic	14		11		3	
Splenic	14		11		3	
Paraspinal	8		7		1	
Mediastinal	7		7		0	
Pulmonary hypertension	8/237	3%	1	2%	7	4%
Leg ulcers	4/240	2%	0	0%	4	2%
Aplastic crises	34/245	14%	6	11%	28	15%
Liver cirrhosis	8/240	3%	2	4%	6	3%
Bone fracture	41/239	17%	7	13%	34	18%
Endocrine dysfunction						
Thyroid disease	11/241	5%	3	6%	8	4%
Growth hormone deficiency	6/236	3%	0	0%	6	3%
Hypoparathyroidism	3/232	1%	1	2%	2	3%
Diabetes	2/250	1%	0	0%	2	1%
Hypogonadal hypogonadism	0/233	0%	0	0%	0	0%
Post pubertal	148/251	59%	39	71%	109	56%
Normal puberty	128/138‡	94%	35	97%	94	92%
Hormones administered	2/115‡	2%	0	0%	2	2%
Slowed/delayed puberty	9/118‡	8%	1	3%	8	9%

Countries (No. of patients enrolled) were United States (154), Germany (31), Italy (25), The Netherlands (23), Canada (14), and Czech Republic (7).

N, total number of patients with data available for the characteristic; n, number of patients per demographic characteristic.

*Some denominators are less than 254 because some patients had unknown data.

†Eleven patients had unknown age at diagnosis.

‡One hundred forty-eight patients were post pubertal; however, some patients had unknown data.

patients (34 [14%] of 245). Extramedullary hematopoiesis was reported in 23 patients, with a significantly higher rate in Amish compared with non-Amish patients ($P < .0001$). There was no report of myelodysplastic syndrome. Leg ulcers were reported in 4 patients age 27 to 42 years at enrollment. Pulmonary hypertension occurred in 8 patients at a median age of 39.2 years (range, 0-42.6 years). The majority of these patients (7 of 8) had

been splenectomized, and 1 was receiving regular transfusions at the time of enrollment. At enrollment, 1% of patients had a previous hepatitis B infection, and 3% had a previous hepatitis C infection.

Bone fractures were reported in 17% of patients. The median 25-hydroxyvitamin D level was 22 ng/mL (range, 9-145 ng/mL).

Table 2. Response to splenectomy

	Response to splenectomy			P*
	No response (Hb < 8 g/dL) (n = 31)	Partial response (Hb 8 to <11 g/dL) (n = 110)	Complete response (Hb ≥ 11) (n = 7)	
Presplenectomy hemoglobin <7 g/dL†	9/16 (56%)‡	12/54‡ (22%)	0/2‡	.007
Age at splenectomy, median (range)	3.7 (0.6-37.8) n = 31	4.1 (0.4-32.2) n = 110	11.7 (1.6-18.6) n = 7	.3
Total bilirubin, mg/dL, median (range)	4.6 (1.1-17.6) n = 27‡	3.7 (1.0-14.3) n = 92‡	2.0 (1.1-3.1) n = 6‡	.005
Absolute reticulocyte count (× 10 ⁶ cells/μL), median (range)	0.8 (0.1-6.5) n = 13‡	0.7 (0.2-5.4) n = 28‡	0.6 (0.5-0.6) n = 3‡	.16
Reticulocyte count (%) median (range)	33.9 (2.5-61.3) n = 20‡	27.1 (4.3-69.3) n = 85‡	16.9 (13.6-30.5) n = 5‡	.11
Currently receiving regular transfusions	6/30 (20%)	13/108 (12%)	0/6 (0%)	.15
Amish	0/31 (0%)	50/110 (46%)	1/7 (14%)	.001
Genotype§				
M/M	9/31 (29%)	34/58 (59%)	6/6 (100%)	.0017
M/N	10/31 (32%)	15/58 (26%)	0/6 (0%)	.0005
N/N	12/31 (39%)	9/58 (16%)	0/6 (0%)	.5

The population for this table is 148 patients who were splenectomized and had known data for response to splenectomy.

Hb, hemoglobin.

*P value from ordinal logistic regression model.

†Median presplenectomy hemoglobin was 6.7 g/dL (range, 5-12.5 g/dL) for the no-response group, 7.5 g/dL (range, 4.5-13.5 g/dL) for the partial response group, and 8.5 g/dL (range, 7-10 g/dL) for the complete response group.

‡Data were available only for subsets of patients (some patients had unknown data).

§Amish participants were excluded from the genotype categories.

||In the ordinal logistic regression model of response to splenectomy, the NM/NM group was the reference group.

A small number of patients had endocrine dysfunction; however, hormone levels were not uniformly monitored in this cohort.

On physical examination, facial jaundice (32%), scleral icterus (58%), bone deformities (9%), and hyperpigmentation (6%) were noted. Splenomegaly was reported in 35% of nonsplenectomized patients.

Surgical treatments

Splenectomy The majority of enrolled patients had a prior splenectomy (150 [59%] of 254), with a higher rate in Amish compared with non-Amish patients ($P < .0001$). Characteristics of the patients by splenectomy status and age distribution at the time of splenectomy are provided in Table 2 and Figure 1. The most common reasons for splenectomy (according to medical record review) were to improve baseline anemia (88%), decrease transfusion burden (85%), improve patient quality of life (83%), and reduce jaundice (57%). In 90% of patients, the transfusion burden was reduced after splenectomy. The reported median change in hemoglobin from pre- to postsplenectomy was 1.6 g/dL (range, -5.5 to 4.9 g/dL [$n = 72$]), with a reduction in hemoglobin noted in some patients when transfusions were discontinued.

Seventy-five percent (98 of 131) of patients age 18 years and older at enrollment had a prior splenectomy compared with 42% (52 of 123) who were younger than age 18 years at enrollment ($P < .0001$). There was no significant difference in age at the time of the first transfusion between patients who had a splenectomy and those who did not ($P = .76$). Univariate

predictors of a poor response to splenectomy, defined as a postsplenectomy hemoglobin <8 g/dL included lower pre-splenectomy hemoglobin ($P = .007$), NM/NM mutations ($P = .0017$), and a higher total bilirubin ($P = .005$; Table 2).


Three patients had a partial splenectomy. Two patients, each of whom had a partial splenectomy at age 4 years, had a hemoglobin level of 6.9 g/dL after partial splenectomy, and both eventually discontinued regular transfusions. The third patient had a partial splenectomy at age 11 years and has continued to receive regular transfusions for 4 years postsurgery.

Postsplenectomy sepsis occurred in 7% of patients. Despite the earlier median age of splenectomy in the Amish cohort, there was no difference in the rate of postsplenectomy sepsis compared with the non-Amish cohort.

Of the 254 patients, 7% (17 of 252) had a history of thrombosis. There was an increased frequency of thrombosis in patients who underwent splenectomy (17 [11%] of 149) vs no occurrences of thrombosis in patients who were not splenectomized ($P = .0001$). Postsplenectomy thrombosis included deep vein thrombosis ($n = 9$), pulmonary embolism ($n = 6$), stroke ($n = 3$), and portal vein thrombosis ($n = 2$). Five patients had more than 1 thrombotic event.

Cholecystectomy Gallstones are a frequent complication of PK deficiency and were reported in 45% (112 of 248) of patients with a median age of 14.3 years (range, 2.2-60.4 years; Figure 2), and

Figure 1. Age at the time of splenectomy. Overall, 150 (59%) of 254 patients had a history of splenectomy at enrollment with median age at splenectomy of 4.1 years (range, 0.4-37.8 years). Among the cohort of Amish patients, 93% had a splenectomy at a median age of 1.6 years (range, 0.6-28.2 years). Among the cohort of non-Amish patients, 50% had a splenectomy at a median age of 5.0 years (range, 0.4-37.8 years).



62% occurred in children younger than age 18 years. Cholecystectomy was performed in 101 (40%) of 254 patients. In patients who had a record of the timing of both procedures ($n = 85$), the cholecystectomy was performed together with splenectomy in 18 (21%) of 85 and after splenectomy in 56 (66%) of 85. Of the 121 patients who underwent splenectomy without a prior or simultaneous cholecystectomy, 58 (48%) required a cholecystectomy at a later time.

Comparing patients who required cholecystectomy with those who did not, there was no significant difference in hemoglobin (median, 8.8 vs 8.9 g/dL, respectively; $P = .78$). Patients who had a cholecystectomy had a significantly higher total bilirubin (median, 4.2 vs 3.4 mg/dL; $P = .0024$), higher absolute reticulocyte count (median, 0.5 vs 0.2×10^6 cells per μL ; $P = .0011$) and older age at diagnosis (median, 0.7 vs 0.3 years, respectively; $P = .04$) than patients who did not have a cholecystectomy.

Spectrum of transfusion requirements

Of 250 patients with a known transfusion history, 210 (84%) had received a blood transfusion in their lifetime. Forty-eight percent of patients (25 of 52) age 5 years and younger received regular transfusions compared with 26% of patients (9 of 35) older than age 5 years to younger than 12 years, 11% (4 of 36) age 12 years to younger than 18 years, and 8% (10 of 127) age 18 years and older ($P < .0001$). Despite the transfusion frequency in this study cohort, only 3% (7 of 231) had allo-immunization, and 2% (5 of 224) had auto-immunization.

The most commonly reported hemolytic triggers for patients were infections (60%), stress (29%), and pregnancy (51%). Medications, including aspirin and/or anti-inflammatories ($n = 6$) and antibiotics ($n = 3$), were uncommon hemolytic triggers.

Patients age 5 years and younger at the time of enrollment

Transfusion requirements are considered separately for patients age 5 years and younger ($n = 52$) and those older than age 5 years ($n = 202$), because splenectomy is usually not performed until after age 5 years. Among the patients age 5 years and younger, 6 (12%) had a splenectomy before enrollment, and 6 (12%) had never been transfused. Twenty-three patients (44%),

all with intact spleens, were regularly transfused; median pre-transfusion hemoglobin was 7.2 g/dL (range, 5.2-8.7 g/dL), median transfusion interval was 5.2 weeks (range, 2.7-8.7 weeks), and median volume of red cells transfused was 15.2 mL/kg.

Patients older than age 5 years at the time of enrollment

Never transfused Of the 202 patients older than age 5 years at the time of enrollment, transfusion history was available for 198 (Table 3). A minority of these patients had never received a blood transfusion (34 [17%] of 198). These patients had a median enrollment age of 28 years (range, 5.9-69.9 years) and were observed at 11 different centers. This cohort had a median hemoglobin of 11 g/dL (range, 9-13.5 g/dL), and 20% (7 of 34) had previously undergone a splenectomy.

Intermittently transfused Approximately one quarter of patients older than age 5 years at enrollment (56 [28%] of 198) received intermittent transfusions but had never been regularly transfused. In this group, 61% (34 of 56) had previously been splenectomized.

Regular transfusions discontinued after splenectomy Most of the patients who historically required regular transfusions (≥ 6 transfusions over a 12-month period) no longer required regular transfusions after splenectomy. Of 79 patients who received regular transfusions up until the time of splenectomy, 62 (78%) were able to discontinue transfusions. In this group, the median hemoglobin was 8.8 g/dL (range, 4.3-12.8 g/dL) after splenectomy, and the median reticulocyte count was 32.3% (range, 4.8%-65%).

Regularly transfused after splenectomy Six patients older than age 5 years were regularly transfused and were not splenectomized. In addition, 17 patients (14% [17 of 124] of all patients splenectomized) continued to receive regular transfusions after splenectomy. The median number of weeks between transfusions in these patients was 5.8 (range, 2.4-8.7 weeks) with a median hemoglobin of 8.1 g/dL (range, 6.7-9.9 g/dL) before transfusion. The median volume of red cells transfused was 9.6 mL/kg. The median age at the time of splenectomy was 5.2 years (range, 2.1-25.8 years). The median reticulocyte count was




Figure 2. Age at the time of cholecystectomy. Cholecystectomy was performed in 101 (40%) of 254 participants overall and in 89 (79.5%) of 112 patients who reported gallstones. Median age at cholecystectomy was 15.1 years (range, 0.6 to 53.7 years).

20.9% (range, 2.5%-44.1%) after splenectomy. Iron overload was more common in these patients (median ferritin, 1178 ng/dL [range, 307-3850 ng/mL]; 16 [94%] of 17 required chelation therapy) than in patients who discontinued regular transfusions after splenectomy (median ferritin, 624 ng/dL [range, 230-2783 ng/mL]; 28 [44%] of 62 required chelation therapy; $P = .02$ and $P = .0002$, respectively).

Laboratory findings Increased lactate dehydrogenase was not common (supplemental Table 2), whereas indirect hyperbilirubinemia was almost always present, with a median total bilirubin of 3.7 mg/dL. Those with a prior splenectomy had a higher reticulocyte count, mean cell volume, and total bilirubin. Median ferritin was 606 ng/mL (range, 17-8080 ng/mL [$n = 180$]) for the overall study cohort. Iron overload was common, even in those who did not receive regular transfusions. Forty-seven percent (87 of 184) of patients had a ferritin level of >1000 ng/mL or had received chelation therapy in the 12 months before enrollment. Ferritin level had not been checked in the year before enrollment in 29% (74 of 254) of patients.

Medications Commonly reported medications in the cohort included folic acid (182 [72%] of 252), iron chelation (83 [23%] of 254), and prophylactic antibiotics (49 [19%] of 253). Of those who had a splenectomy, 5% (12 of 150) were taking aspirin. Patients taking folic acid did not have a significantly different baseline hemoglobin ($P = .4$) or reticulocyte count ($P = .8$).

Genotype-phenotype associations The genotype-phenotype analysis was stratified as 112 patients with M/M mutations (58%), 52 with M/NM (27%), and 29 with NM/NM (15%; Table 4). For patients age 5 years and older at enrollment, all patients in the NM/NM group, 100% vs 62% in the M/NM group, and 56% in the M/M group had been splenectomized ($P < .0001$). Only 3% of the NM/NM group had never had a transfusion vs 18% of the M/NM and 23% of the M/M groups. There were significant differences in the total number of lifetime transfusions ($P = .0015$), with a median of 65 in the NM/NM group compared with medians of 25 in the M/NM group and 16 in M/M group. The NM/NM group had the highest maximum ferritin ($P < .0001$) and was more likely to have iron overload, defined as ferritin

>1000 ng/mL or having received chelation in the year before enrollment ($P = .0013$). Notably, there was no evidence of an association of PK enzyme activity with the genotype.

Discussion

PK deficiency is a rare congenital hemolytic anemia with a diverse phenotype and wide spectrum of severity. A large international cohort of patients with PK deficiency is now followed in this multicenter, global natural history study, which allows for more detailed description of the clinical spectrum, complications, and current management strategies.

Most newborns present with significant jaundice, and about one quarter have had perinatal complications. The diagnosis of PK deficiency should be suspected in patients with perinatal jaundice and hemolysis. However, 10% of patients with PK deficiency in this study cohort did not have perinatal jaundice, so the absence of this feature does not exclude the possibility of PK deficiency. One patient presented with hepatosplenomegaly and hepatic dysfunction leading to hepatic failure, which has previously been reported by other groups.^{12,13} The evaluation of a newborn with noninfectious hepatic failure should include testing for PK deficiency.

Most patients with PK deficiency in this cohort received regular transfusions in early childhood. Young children experience more infectious stressors that lead to hemolytic episodes, and occasionally, young children will be transfused to support growth and development. However, the management of children age 5 years and younger is highly variable: some children have a splenectomy in the early years. The majority delay splenectomy beyond age 5 years but receive regular transfusions, others receive transfusions only for acute triggers, and some have never received a transfusion. This likely reflects both variability in clinical severity and differences in management strategies by hematologists because the hemoglobin nadirs overlap between transfusion groups. Although some newborns with PK deficiency will require transfusions after birth, decreasing the frequency of transfusions to permit a lower hemoglobin nadir will allow assessment of a reticulocyte response. The reticulocyte response may be adequate

Table 3. Transfusion status at the time of enrollment and hemolytic triggers

	Number of patients (n/N with known data)	%	Amish patients	%	Non-Amish patients	%
Transfusion status at enrollment*						
Historically on regular transfusions†	79/198	40	32/46	70	47/152	31
Currently on regular transfusions‡	23§/198	12	0/46	0	23/152	15
Intermittent transfusions only	56/198	28	6/46	13	50/152	33
Never transfused	34/198	17	4/46	9	30/152	20
Historical transfusions with unknown transfusion frequency	6/198	3	4/46	9	2/152	1
Hemolytic triggers						
Presumed infections	137/228	60	41/53	30	96/175	70
Stress	59/207	29	36/54	61	23/153	39
Pregnancy	20/39¶	51	13/41	33	26/89	67
Transfused for an acute stressor	127/247	51	16/52	13	111/195	87
Transfusions in the 12 mo prior to enrollment						
Transfused at least once	92/254	36	5/55	9	87/199	44
Median hemoglobin (range)	8.1 (5.5-11)		8.8 (7.4-9)		8 (5.5-11)	
Not transfused	162/254	64	50/55	91	112/199	56
Median hemoglobin (range)	9.6 (6.3-14.2)		9.5 (8-11.2)		9.6 (6.3-14.2)	

N, total number of patients with known data; n, number of patients.

*The sample size is 202 because 53 children age 5 years and younger were not included in this analysis.

†Historically received regular transfusions is defined as not receiving regular transfusions in the 12 months before enrollment and .6 transfusions per year before the 12-month period before enrollment.

‡Currently receiving regular transfusions is defined as receiving §6 transfusions over the last 12-month period before enrollment.

§Twenty-three patients were receiving regular transfusions at the time of enrollment; 17 had had a splenectomy.

||The denominators are less than 254 because some patients had unknown data for presumed infections, stress, or transfusion for an acute stressor.

¶Thirty-nine female patients had at least 1 pregnancy.

to transition to transfusion independence over time, even without a splenectomy. Because of the high levels of 2,3-diphosphoglycerate, a lower hemoglobin may be more tolerable and favorable in patients with PK deficiency compared with regular transfusions.^{14,15} The need for transfusions should be based on comprehensive clinical judgment regarding quality of life, growth, and symptoms and not on hemoglobin level alone.

In young patients who continue to rely on regular transfusions, the risk of transfusions must be balanced with the risks of splenectomy. On the basis of the data from this cohort, the risk of allo-sensitization is quite low, but transfusional hemosiderosis occurs in all patients, and regular transfusions have important implications for quality of life. The experience of the Amish cohort suggests that splenectomy at a younger age than is typical (younger than age 5 years) may avoid many years of iron loading in young patients who receive regular transfusions, but it comes with a potentially higher risk of serious bacterial infections. Of the 79 patients who were older than age 5 years at the time of enrollment and who received regular transfusions up until the time of splenectomy, 62 (78%) no longer received regular transfusions after splenectomy. Thus, splenectomy is effective for the majority of patients with PK deficiency, in that it allows patients to discontinue regular transfusions and improves anemia. The relationship between age and transfusions, in which older patients have a lower frequency of transfusions, is likely linked to the relationship between age and splenectomy and the effect of splenectomy on decreasing transfusion requirements. Anemia is only partially ameliorated by splenectomy, with a median hemoglobin

of 8.8 g/dL after splenectomy, and 14% of those who underwent a splenectomy continued to require regular transfusions afterward.

Three patients in this cohort had partial splenectomies; one patient continued to be regularly transfused despite the procedure, and two others remained severely anemic after the procedure. These limited data are insufficient to answer the question fully, but based on our limited experience regarding partial splenectomy, full splenectomy seems to be the most beneficial for increasing hemoglobin levels and decreasing the need for transfusion. Although most patients no longer regularly received transfusions after splenectomy, those with a lower hemoglobin before splenectomy and more robust hemolysis were more likely to have a hemoglobin level of <8 g/dL after splenectomy. Thus, although patients with more severe hemolysis typically benefited from splenectomy in terms of transfusion needs, significant hemolysis predicts a less favorable hemoglobin response to splenectomy.

Splenectomized patients are at increased risk of venous thrombosis compared with the nonsplenectomized population.¹⁶ Patients who are splenectomized for hematologic conditions are at further increased risk of thrombosis compared with those splenectomized as a result of trauma. Specific congenital hemolytic anemias, such as hereditary xerocytosis, are associated with such a significantly increased rate of thrombosis after splenectomy, that changes in management have occurred, and splenectomy is often avoided in patients with these conditions.¹⁷ In this study

Table 4. Genotype-phenotype associations in 193 patients with pyruvate kinase deficiency

	NM/NM, N = 29, median (range)	M/NM, N = 52, median (range)	M/M, N = 112, median (range)	P*
Age at diagnosis, y	0.4 (0-10.9) n = 29	0.7 (0-42.3) n = 50	1.3 (0-60.3) n = 106	.049
Hemoglobin, g/dL†	7.9 (6.5-8.9) n = 14	8.4 (6.4-12.8) n = 21	8.9 (4.3-12.3) n = 41	.006
Total number of lifetime transfusions	65 (3-363) n = 27	25 (1-516) n = 38	16 (1-486) n = 81	.0015‡
Maximum ferritin, ng/mL	1787 (423-13409) n = 22	604 (22-8220) n = 37	573 (31-9679) n = 75	<.0001‡
Normalized PK enzyme activity, %	-41.6 (-152.4-15.2) n = 18	-51.9 (-211.1-64.4) n=24	-69.6 (-485.7-117.6) n = 60	.16
	NM/NM, n (%)	M/NM, n (%)	M/M, n (%)	P§
Prenatal complications	11/27 (41)	15/48 (31)	28/99 (28)	.44
Exchange transfusion	9/20 (45)	17/41 (41)	34/79 (43)	1
Rate of splenectomy in patients age ≥5 y	21/21 (100)	26/42 (62)	48/88 (55)	<.0001
Rate of cholecystectomy	13/29 (45)	25/52 (48)	46/112 (41)	.69
Extramedullary hematopoiesis	3/25 (12)	0/43 (0)	5/93 (5)	.066
Iron overload	21/25 (84)	20/38 (53)	33/77 (43)	.0013‡
Never transfused	1/29 (3)	9/51 (18)	26/111 (23)	.036

Amish patients with a homozygous R479H mutation were excluded from this analysis due to management differences, as these patients are typically uninsured and the cost of care can be prohibitive.

*Kruskal-Wallis test.

†Hemoglobin in the splenectomized, not regularly transfused cohort.

‡Statistically significant at $P < .0055$.

§Fisher's exact test.

||Iron overload defined by maximum ferritin >1000 ng/mL, or the patient received chelation in prior 12 months.

cohort of 150 splenectomized patients with PK deficiency, 11% experienced postsplenectomy thrombosis, a rate similar to that described in other hematologic conditions.¹⁸⁻²⁰ Although this important potential complication must be considered, the rates of thrombosis and pulmonary hypertension are not increased enough after splenectomy that splenectomy should be avoided in this patient population.

Gallstones are a frequent complication of PK deficiency at all ages from 2.2 to 60.4 years. Splenectomy does not decrease the risk of gallstones in patients with PK deficiency; thus, splenectomized patients with PK deficiency remain at risk for the development of pigmented gallstones. In this cohort, most patients who ultimately had both a cholecystectomy and a splenectomy had these surgeries performed separately. We conclude that just before splenectomy, all patients with PK deficiency should be screened for gallstones by ultrasound. If gallstones are present, concurrent cholecystectomy should be considered, because asymptomatic pigmented gallstones may lead to unnecessary complications. However, given the risk of complications from gallstones and a nearly 50% likelihood of a later cholecystectomy, cholecystectomy should be considered for all patients with PK deficiency at the time of splenectomy, regardless of the presence of gallstones by ultrasound.

The risk of transfusional hemosiderosis is a well-recognized, obligatory complication of regular transfusion therapy. Transfusion-independent iron loading in PK deficiency is under-recognized, occurring at all ages and in patients with both mild and more severe anemia. Approximately one quarter of the patients with PK deficiency in this cohort had not had ferritin levels checked in the year before enrollment. Because iron loading is common in PK deficiency, affected patients should have their iron levels monitored at least once per year. Patients with PK deficiency in this cohort also seemed to be at risk for bone disease and had bone deformities on physical examination along with a high rate of fractures. Bone disease is a common complication of thalassemia syndromes because of marrow expansion, iron toxicity and treatment, increased bone turnover, and hormone deficiencies.²¹ Patients with PK deficiency may be at similar risk for osteopenia; thus, close attention to vitamin D and calcium intake may be beneficial, and monitoring with dual-energy x-ray absorptiometry scans should be considered for baseline assessment in late adolescence or early adulthood.

A genotype-phenotype relationship was identified in this international cohort, in which patients with 2 M/M mutations in the *PKLR* gene had a lower likelihood of splenectomy, fewer lifetime transfusions, and a lower rate of iron overload. Patients with

2 NM/NM mutations were less likely to have a complete or partial response to splenectomy. Therefore, pursuing molecular testing may be useful in discussing prognosis and establishing a monitoring plan with patients on the basis of their genotyping results. Although a genotype-phenotype correlation was identified, there is a high frequency of complications in all genotypes. In addition, the ranges of hemoglobin levels were overlapping among the genotype groups, and so the genotype may not be predictive of clinical phenotype in some patients. Although genotyping in a young child can help predict the likelihood of complications, certain types of monitoring are needed in all patients.

The data from the Pyruvate Kinase Deficiency Natural History Study were limited by the nature of natural history studies and by patient registries shared among rare diseases. Despite the present global effort and large number of sites, a limited number of patients were available for data capture. Furthermore, deceased patients who may have had significant disease-related complications were not included, and only those with a laboratory diagnosis were included, thus excluding undiagnosed patients. In addition, patient or provider bias may have had an impact on historical data when medical records were not available. Furthermore, laboratory data, other assessments, and treatments such as splenectomy and transfusions were biased by provider practices, types of routine monitoring, and missing data.

The data from the Pyruvate Kinase Deficiency Natural History Study show few early clinical predictors of a later more severe clinical course. Serious complications including gallstones, iron overload, and osteopenia occurred even in those patients with nearly normal hemoglobin values, and serious but rare complications included pulmonary hypertension, extramedullary hematopoiesis, and lower extremity ulcerations in the cohort overall. Close monitoring and attention is needed in these patients, even in those with mild anemia. Despite these complications, life expectancy seems to be long. Together with the absence of predictors for disease severity, the potential for serious complications highlights the importance of close monitoring and follow-up of these patients by a hematologist, even for those patients with mild anemia.

REFERENCES

1. Tanaka KR, Valentine WN, Miwa S. Pyruvate kinase (PK) deficiency hereditary nonspherocytic hemolytic anemia. *Blood*. 1962;19:267-295.
2. Nathan DG, Oski FA, Miller DR, Gardner FH. Life-span and organ sequestration of the red cells in pyruvate kinase deficiency. *N Engl J Med*. 1968;278(2):73-81.
3. Mentzer WC Jr, Baehner RL, Schmidt-Schönbein H, Robinson SH, Nathan DG. Selective reticulocyte destruction in erythrocyte pyruvate kinase deficiency. *J Clin Invest*. 1971;50(3):688-699.
4. Beutler E, Gelbart T. Estimating the prevalence of pyruvate kinase deficiency from the gene frequency in the general white population. *Blood*. 2000;95(11):3585-3588.
5. Carey PJ, Chandler J, Hendrick A, et al; Northern Region Haematologists Group. Prevalence of pyruvate kinase deficiency in

- northern European population in the north of England. *Blood*. 2000;96(12):4005-4006.
6. Rider NL, Strauss KA, Brown K, et al. Erythrocyte pyruvate kinase deficiency in an old-order Amish cohort: longitudinal risk and disease management. *Am J Hematol*. 2011;86(10):827-834.
7. Pissard S, Max-Audit I, Skopinski L, et al. Pyruvate kinase deficiency in France: a 3-year study reveals 27 new mutations. *Br J Haematol*. 2006;133(6):683-689.
8. Lenzner C, Nürnberg P, Jacobasch G, Gerth C, Thiele BJ. Molecular analysis of 29 pyruvate kinase-deficient patients from central Europe with hereditary hemolytic anemia. *Blood*. 1997;89(5):1793-1799.
9. Zanella A, Fermo E, Bianchi P, Chiarelli LR, Valentini G. Pyruvate kinase deficiency: the genotype-phenotype association. *Blood Rev*. 2007;21(4):217-231.
10. Zanella A, Bianchi P. Red cell pyruvate kinase deficiency: from genetics to clinical

- manifestations. *Best Pract Res Clin Haematol*. 2000;13(1):57-81.
11. Grace RF, Zanella A, Neufeld EJ, et al. Erythrocyte pyruvate kinase deficiency: 2015 status report. *Am J Hematol*. 2015;90(9):825-830.
12. Olivier F, Wieckowska A, Piedboeuf B, Alvarez F. Cholestasis and hepatic failure in a neonate: a case report of severe pyruvate kinase deficiency. *Pediatrics*. 2015;136(5):e1366-e1368.
13. Raphaël MF, Van Wijk R, Schweizer JJ, et al. Pyruvate kinase deficiency associated with severe liver dysfunction in the newborn. *Am J Hematol*. 2007;82(11):1025-1028.
14. Delivoria-Papadopoulos M, Oski FA, Gottlieb AJ. Oxygen-hemoglobin dissociation curves: effect of inherited enzyme defects of the red cell. *Science*. 1969;165(3893):601-602.
15. Oski FA, Marshall BE, Cohen PJ, Sugerman HJ, Miller LD. The role of the left-shifted or

Acknowledgments

The authors acknowledge all the patients with pyruvate kinase deficiency who contributed to this Natural History Study data and Anran Li for her assistance with statistical analysis.

The Pyruvate Kinase Deficiency Natural History Study was supported by research funding from Agios Pharmaceuticals.

Authorship

Contribution: R.F.G. conceived the study, analyzed and interpreted the data, and wrote the manuscript; W.B., A.Z., J.M.D., B.G., H.M.Y., S.W.E., E.J.v.B., M.S., M.M.M., P.B., and J.A.R. conceived the study, interpreted the data, and provided critical revisions to the manuscript; D.H.M., S.C., E.J.N., N.K., C.M.K., K.K., J.L.K., D.P., Y.D.P., P.E.N., Y.R., A.A.T., W.C.W., M.W.W., H.W., J.K., V.R.B., M.J.R., H.A.B., S.S., S.C., N.N., S.H., E.F., K.L.-G., and P.G.G. performed the research and contributed to the manuscript; and D.G., H.A.-S., and W.B.L. analyzed and interpreted the data and contributed to the manuscript.

Conflict-of-interest disclosure: R.F.G., P.B., H.M.Y., J.A.R., E.J.N., W.B., B.G., S.W.E., E.J.v.B., K.K., Y.R., S.C., and J.L.K. are scientific advisers to Agios Pharmaceuticals. R.F.G., E.J.v.B., B.G., H.M.Y., D.H.M., K.K., J.L.K., Y.R., S.S., W.B., and P.G.G. receive research funding from Agios Pharmaceuticals. The remaining authors declare no competing financial interests.

ORCID profile: R.F.G., 0000-0001-7302-0449.

Correspondence: Rachael F. Grace, Dana-Farber/Boston Children's Cancer and Blood Disorder Center, 450 Brookline Ave, D3-106, Boston, MA 02215; e-mail: rachael.grace@childrens.harvard.edu.

Footnotes

Submitted 24 October 2017; accepted 2 March 2018. Prepublished online as *Blood* First Edition paper, 16 March 2018; DOI 10.1182/blood-2017-10-810796.

The online version of this article contains a data supplement.

There is a *Blood* Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

- right-shifted oxygen-hemoglobin equilibrium curve. *Ann Intern Med.* 1971;74(1):44-46.
16. Thomsen RW, Schoonen WM, Farkas DK, Riis A, Fryzek JP, Sørensen HT. Risk of venous thromboembolism in splenectomized patients compared with the general population and appendectomized patients: a 10-year nationwide cohort study. *J Thromb Haemost.* 2010;8(6):1413-1416.
17. Stewart GW, Amess JA, Eber SW, et al. Thrombo-embolic disease after splenectomy for hereditary stomatocytosis. *Br J Haematol.* 1996;93(2):303-310.
18. Thai LH, Mahévas M, Roudot-Thoraval F, et al. Long-term complications of splenectomy in adult immune thrombocytopenia. *Medicine (Baltimore).* 2016;95(48):e5098.
19. Mohren M, Markmann I, Dworschak U, et al. Thromboembolic complications after splenectomy for hematologic diseases. *Am J Hematol.* 2004;76(2):143-147.
20. Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. *Blood.* 2014;124(19):2930-2936.
21. Vogiatzi MG, Macklin EA, Fung EB, et al; Thalassemia Clinical Research Network. Bone disease in thalassemia: a frequent and still unresolved problem. *J Bone Miner Res.* 2009;24(3):543-557.